|
|
|
|
|
|
|
PEER-TO-PEER CLINICAL CONVERSATIONS |
|
|
|
|
|
|
The Role of Liquid Biopsy in the Management of Patients with Genitourinary Malignancies
|
|
Benjamin Maughan, MD, PharmD
|
| Ashish Kamat is joined by Benjamin Maughan to discuss the evolution and clinical applications of liquid biopsy technology in bladder cancer. Dr. Maughan traces the progress over the past three to four years, highlighting how the expansion of treatments targeting specific genomic alterations has occurred alongside significant technological improvements.
|
|
|
|
|
|
|
|
|
|
|
|
|
Survey Uncovers Evolving Trends in Advanced Bladder Cancer Care
|
Ali Raza Khaki, MD
Zachary Klaassen speaks with Ali Khaki about a survey examining treatment decisions after prior immune checkpoint inhibitor exposure in urothelial carcinoma. With the boom in immunotherapy moving into earlier disease stages—including EV-pembrolizumab approval for first-line metastatic disease and various non-muscle invasive studies—the key question became whether immunotherapy remains viable after prior exposure.
|
|
|
|
|
|
|
|
|
|
|
|
Evaluating Chemotherapy De-Escalation in First-Line Urothelial Carcinoma: DISCUS Trial
|
|
Enrique Grande, MD, PhD, MSc
|
| Professor Enrique Grande joins Ashish Kamat to discuss the DISCUS trial, a phase II study comparing three versus six cycles of platinum-based chemotherapy before avelumab maintenance in first-line metastatic urothelial carcinoma.
|
|
|
|
|
|
|
|
|
|
|
|
Reduced-Dose Enfortumab Vedotin, Treatment Continuity, and Survival in Urothelial Cancer - Beyond the Abstract
|
| Henry K. Litt, MD, Ronac Mamtani, MD, MSCE, and Ryan D. Chow, MD
|
| This analysis of nearly 500 patients treated with first-line enfortumab vedotin plus pembrolizumab shows that starting EV at a reduced dose cut the risk of treatment interruption in half without significantly worsening overall survival. The authors suggest that proactive dose reduction, particularly in older or physiologically vulnerable patients, can improve tolerability and maintain efficacy, highlighting that maximizing dose intensity is not always necessary to preserve clinical benefit.
|
|
|
|
|
|
| DISCUS: A Phase II Study Comparing 3 Versus 6 Cycles of Platinum-Based Chemotherapy Prior to Maintenance Avelumab in Advanced Urothelial Cancer
|
| Enrique Grande, MD, PhD, MSc
|
| Enrique Grande presents DISCUS data showing that three cycles of first-line platinum-based chemotherapy followed by maintenance avelumab provide better patient-reported quality of life than six cycles, with an 8.5‑point advantage on the EORTC QLQ-C30 global health scale and fewer grade 3–4 adverse events.
|
|
|
|
|
|
| Surgical Consolidation in Advanced Urothelial Carcinoma After Enfortumab Vedotin and Immune Checkpoint Inhibitor - Expert Commentary
|
| Bishoy Faltas, MD
|
| This expert commentary reviews a retrospective multicenter series of 28 patients with advanced urothelial carcinoma who underwent consolidative radical cystectomy or nephroureterectomy after induction enfortumab vedotin plus immune checkpoint inhibitor therapy. Pathologic downstaging occurred in 82% of patients, including a 43% pathologic complete response rate, and nearly 90% of those operated on with curative intent remained disease-free at short follow-up, with acceptable surgical complication rates.
|
|
|
|
|
|
|
|
|
|
|
Treatment Outcomes after Progression on Enfortumab Vedotin in Patients with Advanced Urothelial Carcinoma - Expert Commentary
|
| Bishoy Faltas, MD
|
| Bishoy Faltas reviews a small retrospective study of patients with advanced urothelial carcinoma who progressed on enfortumab vedotin, showing that subsequent chemotherapy or immune checkpoint inhibitors provided limited benefit, with overall survival around 4–5 months and no clear advantage over best supportive care.
|
|
|
|
|
|
| Health Related Quality of Life Outcomes from the NIAGARA Trial of Perioperative Durvalumab + Neoadjuvant Chemotherapy in MIBC
|
| Michiel Van der Heijden, MD, PhD
|
| NIAGARA quality-of-life data show that adding perioperative durvalumab to cisplatin–gemcitabine neoadjuvant chemotherapy and radical cystectomy improves event-free and overall survival without compromising health related quality of life. Across EORTC QLQ-C30 global health, physical functioning, fatigue, pain, and EQ-5D-5L scores, both arms experienced similar temporary declines around surgery that later improved, with no clinically meaningful differences or faster deterioration in the durvalumab arm.
|
|
|
|
|
|
|
|
|
|
|
